Lupin rises on getting tentative approval for Ivacaftor Tablets from USFDA

08 Jun 2022 Evaluate

Lupin is currently trading at Rs. 612.10, up by 2.20 points or 0.36% from its previous closing of Rs. 609.90 on the BSE.

The scrip opened at Rs. 607.00 and has touched a high and low of Rs. 614.60 and Rs. 603.00 respectively. So far 89358 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1258.75 on 09-Jun-2021 and a 52 week low of Rs. 583.05 on 25-May-2022.

Last one week high and low of the scrip stood at Rs. 621.55 and Rs. 598.10 respectively. The current market cap of the company is Rs. 27827.72 crore.

The promoters holding in the company stood at 46.78%, while Institutions and Non-Institutions held 41.85% and 11.37% respectively.

Lupin has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ivacaftor Tablets, 150 mg, to market a generic equivalent of Kalydeco Tablets, 150 mg of Vertex Pharmaceuticals Incorporated. This product will be manufactured at Lupin’s Nagpur facility in India. Ivacaftor Tablets (RLD: Kalydeco Tablets) had estimated annual sales of $109 million in the U.S.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2198.25 12.00 (0.55%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.